The aim of the project is to study the effect of GRTs on the synthesis and cytokine release in psoriasis lesions. Thisinformation can establish the right formulation and dose of GRTs for further research.
ID
Source
Brief title
Condition
- Epidermal and dermal conditions
Synonym
Research involving
Sponsors and support
Intervention
Outcome measures
Primary outcome
Cytokine synthesis and release after treatment with GRTs.
Secondary outcome
-
Background summary
Psoriasis is an autoimmune disease in which proinflammatory protein mediators,
released by skin cells and infiltrating
cells, cause an abnormal cell division and differentiation. It may be possible
to treat psoriasis using drugs aimed at
preventing the synthesis of such mediators.
Study objective
The aim of the project is to study the effect of GRTs on the synthesis and
cytokine release in psoriasis lesions. This
information can establish the right formulation and dose of GRTs for further
research.
Study design
Lesional skin biopsies of 3 mm in diameter will be treated with GRTs in vitro.
By measuring the effect of the cytokine
synthesis and release, it is possible to establish the right formulation and
dose of the GRTs for further research.
Study burden and risks
The health risks associated with taking skin biopsies are small. It is possible
to obtain a slight scar formation and/or
discolouration at the site of the biopsy punch.
Wytemaweg 80
Rotterdam 3015 CN
NL
Wytemaweg 80
Rotterdam 3015 CN
NL
Listed location countries
Age
Inclusion criteria
Patients with moderate to severe psoriasis
Exclusion criteria
Volunteers undergoing UV/light therapy or taking systemic drugs such as cyclosporin A or methotrexate
Volunteers using local topical corticosteroids
Volunteers developing psoriasis at wound sites (Köbner phenomenon)
Design
Recruitment
metc-ldd@lumc.nl
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
| Register | ID |
|---|---|
| CCMO | NL59091.098.16 |